Anti-CD20 and Anti-CD27 Combination Therapy for B-cell Lymphoma

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for B-cell lymphoma and other B-cell related diseases, such as rituximab, have limitations in achieving durable remissions and are often accompanied by relapse, necessitating the need for novel therapeutic agents that can enhance the depth and duration of remissions.

Innovation Solution

The use of a combination therapy involving a binding molecule capable of binding to B-cells and promoting their killing, in conjunction with an immunostimulatory agent that stimulates NK and/or T cells, specifically utilizing anti-CD20 and anti-CD27 binding molecules to enhance the efficacy of B-cell depletion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If rituximab monotherapy is used to treat B-cell lymphoma, then the treatment is simple and well-tolerated, but the remission depth is insufficient and relapse occurs in approximately 30% of DLBCL cases

Engineering Contradiction:

Improvetreatment simplicityVSAvoidremission durability

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent combines rituximab (anti-CD20 monoclonal antibody) with lenalidomide (immunomodulatory agent) to create a synergistic combination therapy. This merging of two different mechanisms of action enhances remission depth and durability while managing treatment complexity through established administration protocols.

Inventive Principle:

Principle #5Merging (Combining)

2Duration of action of stationary object

If consolidation with autologous stem cell transplant is performed to achieve durable remissions, then remission duration may be extended, but only 50% of cases achieve durable remissions and the treatment complexity increases significantly

Engineering Contradiction:

Improveremission durationVSAvoidtreatment complexity

Core Design Contradiction:

Duration of action of stationary objectVSDevice complexity

Solution Approach 1:

The patent changes the therapeutic parameters by introducing lenalidomide at specific dosages (e.g., 25mg, 50mg, or 100mg daily) combined with rituximab at standardized doses (375mg/m²). This parameter optimization achieves enhanced remission durability without requiring the complex procedural intervention of stem cell transplantation.

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If successive different therapies are administered with each relapse of indolent lymphoma, then the disease course is managed, but the remission duration becomes increasingly shorter and treatment complexity increases

Engineering Contradiction:

Improvetreatment flexibilityVSAvoidremission duration

Core Design Contradiction:

Adaptability or versatilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary action by using the rituximab-lenalidomide combination therapy to deepen the initial remission and potentially achieve longer-lasting responses. This preventive approach aims to extend remission duration from the outset rather than managing successive relapses with increasingly complex therapy sequences.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This combination therapy significantly enhances the potency of B-cell depletion, leading to increased myeloid cell infiltration at the tumor site, which augments the anti-B-cell monoclonal antibody activity, potentially resulting in more effective treatment and prevention of B-cell related diseases.

Implementation Method 1

The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP)

Methodology Applied

Scientific EffectAntibody directed cellular cytotoxicity (ADCC):

Implementation Method 2

Methodology Applied

Scientific EffectPhagocytosis:

Implementation Method 3

an immunostimulatory agent arranged to stimulate NK and/or T cell activation

Methodology Applied

Scientific EffectImmune cell stimulation:

Data Source

PatentUS12325754B2Cancer and B-cell related disease therapy

Publication Date: 2025.06.10 UNIV OF SOUTHAMPTON

AI summary

The disclosure relates to a method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell; and an immunostimulatory agent arranged to stimulate effector lymphocytes, such as NK and/or T cells. Additionally, an anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject. The disclosure also relates to a method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell; and an immunostimulatory agent arranged to stimulate NK and/or T-cell activation. Additionally, an anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.